Delivered revenues of `4,786 Crore
in FY2019, growing 11% y-o-y and
contributing 36% to overall PEL revenue
mix
Strong presence in regulated markets
Strong focus in the areas of quality,
compliance and reliability helped
consistent revenue growth since
FY2011, despite challenging business
environment
Global Pharma EBITDA grew at a CAGR of
24% over last 3 years
Global Pharma EBITDA margins at 23% in
FY2019 as compared to 10% in FY2011
Margin expansion primarily driven by
synergies from acquisitions, growth
from high margin businesses, niche
manufacturing capabilities, higher
capacity utilisation, process optimisations,
global distribution presence, cost
improvement initiatives, and backward
integration of raw material
Our differentiated business model has enabled us to perform better than most other Indian pharma companies
Over 90% of revenues derived from niche businesses of complex generics and Contract Development and Manufacturing Operations (CDMO), as compared with less than 5% for most large Indian Pharma companies
Built strong capabilities in High Potency Active Pharmaceutical Ingredients and Antibody Drug Conjugates
Positioned ourselves as partner of choice for large Global Pharma and virtual Biotech companies
Built niche capabilities in complex products such as injectable anesthesia, inhalation anesthesia, intrathecal spasticity etc.
Business seeing recovery post GST impact with H2 FY2019 revenues up 30% as compared to H1 FY2019
Tapping ecommerce, rural, exports and alternate opportunities in order to widen the distribution network
Using analytics for developing sales strategy and setting credit limits for distributors
Improving reach to match complete product availability and reducing
stock-outs